Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Last week, the FDA finally took action on the dangers of fluoroquinolones antibiotic use opening the door for antibiotic lawsuits.
According to the FDA Safety Communication,
Systematic use of fluoroquinolones (such as Cipro, Levaquin, Avelox, Floxin and Factive) is associated with disabling and potentially permanent serious side effects that can occur together. These side effects can involve the tendons, muscles, joints, nerves and central nervous system.
The FDA Advisory Panel that heard from 30 members of the public in November 2015, recommended the use of the term “fluoroquinolones associated disability” (or FQAD) to describe these potentially permanent serious side effects that can occur together.
But in May 2016, the FDA stopped short of naming this disability.
Despite the lack of a name, these serious side effects will now be the subject of a strengthened warning on the fluoroquinolone family of antibiotics, which includes such drugs as Levaquin, Cipro, Avelox, Factive, and Floxin.
These labels will now include a “limitation of use” so that it is no longer appropriate for medical professionals to prescribe one of these antibiotics to treat sinusitis, bronchitis or an uncomplicated urinary tract infection.
According to the FDA,
serious side effects associated with these popular antibacterial drugs outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options.
In November 2015, thirty otherwise healthy individuals described some of the serious side effects that became a serious disruption to their lives.
While these injuries vary from person to person, some reported injuries include aortic dissection, aortic aneurysms, peripheral neuropathy and the constellation of disorders affecting the tendons, muscles, joints, nerves and central nervous system.
Lawsuits on behalf of individuals living with these serious injuries are being filed against the manufacturers of Levaquin, Cipro, Avelox, Factive and Floxin alleging that these drugs put individuals at risk of injury without warning.
Fluoroquinolones (FQs) have been used for over 20 years and critics note that they are overprescribed.
According to the CDC, FQs are the fourth-most prescribed antibiotic nationwide – prescribed to 33 million Americans in 2013 alone.
In the past few years, advocates have worked hard to get the word out about the serious side effects from FQ toxicity.
These individuals, many of whom are currently suffering from these life-altering side effects, refer to these collective injuries as “floxing” and “antibiotic toxicity.”
They have set up Facebook pages and website in an effort to get the word out through social media.
The FDA warning and label change will be helpful in these efforts to get the word out to the public, but also to get word to health care professionals who often come up with no specific diagnosis for the constellation of symptoms from these antibiotics.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Fresenius Kabi USA, LLC has announced a corrective Class I recall of an infusion pump software, LVP Software, that runs on the Ivenix Infusion System (IIS). Initiated by the firm on March 7, 2024, the action comes after multiple software anomalies were identified and found
According to the FDA, 20-ounce packages of “King Kullen Broccoli Cutlets with Bread Crumbs and Parmesan” have been recalled by New Haven, Connecticut-based Gracie’s Kitchen due to the potential presence of undeclared sesame and wheat. Individuals who live with allergies to either allergen are advised
The FDA is warning consumers of a Class I recall of Boston Scientific’s Obsidio Comformable Embolic because the device has been shown to present a risk for increased bowel ischemia when used for lower GI (gastrointestinal) bleeding, or acute colonic bleeding. As a pre-mixed embolic